Events

Upcoming Events

September 6-10, 2014
XIVth International Symposium on Proteinases, Inhibitors and Biological Control, Portorož, Slovenia
Olga Vasiljeva, Ph.D., giving presentation titled, "Visualization of Protease Dependent Activation of an Anti-Jagged Probody™ Therapeutic in Human Tumor Biopsies”

September 22-24, 2014
7th Annual International Partnering Conference - BioPharm America 2014, Boston
Debanjan Ray, vice president of business development and alliance management, participating in panel titled "Clinical outlook for new immuno-oncology treatments"

September 30, 2014
BBC Cancer Advance Conference at Harvard Medical School
Sean McCarthy, D. Phil, chief executive officer, will moderate a panel titled, "Innovation in Funding and Deal-Making"

October 14, 2014
7th Annual Sofinnova Japan Biopharma Partnering Conference, Tokyo, Japan

October 26-29, 2014
ADC World Summit, San Diego

November 3, 2014
6th Annual PEGS Europe: Protein & Antibody Engineering Summit, Lisbon, Portugal
Jim West, Ph.D., giving presentation titled, "The Probody Platform Enables Tumor-Specific Targeting of Widely-Expressed Antigens"

November 11, 2014
European Antibody Congress, Geneva
Henry Lowman, Ph.D., chief scientific officer, giving a presentation titled, "Preclinical development of Probody drug conjugates"

Past Events

July 7, 2014
Oncology Partnering and Deal-Making Conference: Advances and Technologies in Oncology, Boston
Debanjan Ray, vice president of business development and alliance management, presenting.

June 25-June 27, 2014
4th International Conference: Notch Targeting in Cancer, Mykonos, Greece

June 7, 2014
The Bay Area Biotechnology Symposium: Pharmaceuticals for the Future, San Francisco
Henry Lowman, Ph.D., chief scientific officer, scheduled to give a presentation titled “Targeting Antibodies Specifically to Diseased Tissues with the Probody™ Platform”

June 2, 2014
Jefferies 2014 Global Healthcare Conference, New York City
Sean McCarthy, D. Phil, chief executive officer, gave a company presentation and overview at 11 a.m. EDT.

April 29, 2014
Allicense 2014 – The Next Generation of Dealmaking in San Francisco
Sean McCarthy, CEO, CytomX Therapeutics Inc participated on a panel titled "The Next Gen of biotech": exploring partnership strategies from a private company CEO’s perspective. The panel took place at 3:30 p.m. PT at the Palace Hotel.

April 5-9, 2014
AACR Annual Meeting 2014, San Diego

Two posters will be presented by CytomX scientists on Monday, April 7, 2014 from 1:00-5:00 p.m. (PT). Details as follows:

Presentation Title: An anti-Jagged- 1/-2 Probody demonstrates inhibition of Jagged-dependent Notch signaling and is activated in multiple types of tumors
Location: Hall A-E, Poster Section 31
Poster Board Number: 25

Presentation Title: Transforming Notch ligands into tumor-antigen targets: A Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2
Location: Hall A-E, Poster Section 31
Poster Board Number: 26

March 31-April 2, 2014
Human Antibodies & Hybridomas 2014, Vienna, Austria
Henry Lowman, Ph.D., chief scientific officer, delivered a presentation on April 1 titled “Targeting antibodies specifically to diseased tissues with Probodies”

March 25-26, 2014
Boston Biotech Business Development Conference, Boston

January 13-17, 2014
Cambridge Healthtech Institute's 12th Annual PEP Talk: The Protein Sciences Week Pipeline 3: Biotherapeutics, Palm Springs, California

January 11-12, 2014
BBC East West CEO Conference, San Francisco

December 12, 2013
Probodies Expand the Therapeutic Index of Antibodies and ADCs, Huntington Beach, California

December 10-14, 2013
San Antonio Breast Cancer Symposium, San Antonio

December 7-10, 2013
2013 ASH Annual Meeting, New Orleans

November 5, 2013
BIOEurope 2013, Vienna, Austria

October 19-23, 2013
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston

October 14-17, 2013
World ADC Summit, San Francisco

October 8-9, 2013
12th Annual BIO Investor Forum, San Francisco

September 19, 2013
Cancer Advance Conference, Boston
Sean McCarthy, D. Phil., chief executive officer, participated in panel titled, "Cancer in 15 Years: Predictions"

June 24-26, 2013
The 30th International Conference On Advances in the Applications of Monoclonal in Clinical Oncology and Symposium on Cancer Stem Cells, Mykonos, Greece
James West, Ph.D., research fellow at CytomX, delivered a presentation titled “The Probody™ Platform Enables Tumor Targeted Therapies.” Jason Sagert, senior scientist, delivered a presentation titled “An Anti-Jagged Probody Enables Tumor-specific Inhibition of Jagged-Dependent Notch Signaling.”

June 26-28, 2013
The Third International Conference on Notch Targeting in Cancer, Mykonos, Greece
James West, Ph.D., research fellow at CytomX, delivered a presentation titled "Probodies: protease activated antibodies for disease-specific inhibition of Notch Signaling". Jason Sagert, senior scientist, delivered a presentation titled "An Anti-Jagged Probody Enables Tumor-specific Inhibition of Jagged-Dependent Notch Signaling."

June 12, 2013
Empowered Antibodies Congress 2013, Barcelona
Sean McCarthy, D. Phil., chief executive officer, delivered a presentation titled "Probody™ therapeutics expand the universe of potential ADC targets."

May 3, 2013
Ninth Annual PEGS, Boston
Henry Lowman, Ph.D., chief scientific officer, delivered a presentation titled "Probody™ Therapeutics Enable an Expanded Universe of ADC Targets."

April 9, 2013
AACR Annual Meeting, Washington, D.C.
Luc Desnoyers, Ph.D., director of cell biology, delivered an oral presentation titled "Development of a Proteolytically Activatable EGFR Probody™ for Cancer Therapy" during the "Back to the Future" mini-symposium.

January 28, 2013
Keystone Symposium on Antibodies as Drugs, Vancouver
Henry Lowman, Ph.D., chief scientific officer, presented a short talk titled, "Probody™ Therapeutics: A New Class of Proteolytically Activated Antibodies."

January 7, 2013
Biotech Showcase, San Francisco
Sean McCarthy, D. Phil, chief executive officer, delivered an overview of the company.

January 6, 2013
East / West CEO Conference, San Francisco
Sean McCarthy, D. Phil, chief executive officer, participated as a speaker at the "West Coast and International Perspectives" session.

November 14, 2012
BIO-Europe, Hamburg, Germany
Sean McCarthy, D. Phil, chief executive officer, presented an overview of the company.

November 9, 2012
Human Antibodies and Hybridomas, Orlando, Florida
Henry Lowman, Ph.D., chief scientific officer, delivered a presentation titled "Preclinical efficacy and safety of Probody™ therapeutics."

June 25, 2012
Next Generation Protein Therapeutics Summit, San Diego
Henry Lowman, Ph.D., chief scientific officer, presented on “Safety and Efficacy of Probody™ Therapeutics in Preclinical Models”

June 18, 2012
2012 BIO International Convention, Boston

May 30, 2012
Euro-Biotech Partnering Summit, Paris

April 29, 2012
PEGS Biologics Partnering Forum, Boston

February 19, 2012
Molecular Med Tri-Con 2012, San Francisco
Henry Lowman, Ph.D., chief scientific officer, delivered a presentation titled “Proteolytically Activated Antibodies have the Potential to Expand Therapeutic Index and Open Up New Target Space.”

January 9, 2012
BioTech Showcase, San Francisco
Sean McCarthy, D. Phil, chief executive officer, presented an overview of the company.

December 6, 2011
IBC Antibody Engineering / Therapeutics Conference, San Diego
Henry Lowman, Ph.D., chief scientific officer, presented.

November 7 - 9, 2011
Human Antibodies and Hybridomas Conference, Cannes, France
Henry Lowman, Ph.D., chief scientific officer, presented.

November 1, 2011
BioEurope – 2011, Dusseldorf, Germany

October 24 - 26, 2011
BioNetwork West, Laguna Niguel, California

June 22, 2011
Next Generation Protein Therapeutics Summit, San Francisco
Henry Lowman, Ph.D., vice president of research, presented.